ストックスクリーナーアプリを入手
2.99
4.91%
0.14
Chimerix Inc (CMRX) 最新ニュース
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
HC Wainwright Has Positive Outlook of Chimerix Q4 Earnings - Defense World
HC Wainwright Has Bullish Forecast for Chimerix Q4 Earnings - MarketBeat
Drugmaker seeks accelerated breakthrough for brain cancer treatment - The Business Journals
Wedbush Analysts Reduce Earnings Estimates for Chimerix - MarketBeat
Wedbush Brokers Lower Earnings Estimates for Chimerix - MarketBeat
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy (NASDAQ:CMRX) - Seeking Alpha
Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat
Chimerix stock touches 52-week high at $2.20 amid market fluctuations - Investing.com Canada
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Can - GuruFocus.com
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Dr - Asianet Newsable
S&P 500 Edges Lower; AutoZone Posts Downbeat EarningsAutoZone (NYSE:AZO), Chimerix (NASDAQ:CMRX) - Benzinga
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy - Yahoo Finance
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? - AOL
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Falls 150 Points; Oracle Posts Downbeat Results - Benzinga
Chimerix Pursues FDA Approval for Dordaviprone - TipRanks
Pre-market Movers: CMRX, CPIX, PCSA, CRDF, VRAR… - RTTNews
Chimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug Dordaviprone - MarketWatch
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End - The Manila Times
Chimerix to File FDA Application for Breakthrough Brain Cancer Drug with 28% Response Rate - StockTitan
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug - MSN
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Chimerix Awards Key Stock Options to New Employees in Strategic Talent Acquisition Move - StockTitan
Chimerix (FRA:CXF) Shares Outstanding (EOP) : 89.94 Mil (As of Sep. 2024) - GuruFocus.com
CMRX (Chimerix) Financial Strength : 5 (As of Sep. 2024) - GuruFocus.com
Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail
CMRX (Chimerix) Debt-to-EBITDA : -0.01 (As of Sep. 2024) - GuruFocus.com
Chimerix (FRA:CXF) Change In Receivables : €-0.13 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wedbush Reiterates Outperform Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix updates officer severance plan, extends term - Investing.com
Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone - StreetInsider.com
Chimerix Cancer Drug Shows 28% Response Rate in Phase 2 Brain Tumor Trial | CMRX Stock News - StockTitan
Wedbush Reaffirms “Outperform” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Chimerix Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Earnings call: Chimerix reports progress and financials for Q3 2024 - Investing.com India
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus.com
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... - Yahoo Finance
Chimerix: Q3 Earnings Snapshot - CT Insider
Chimerix Inc (CMRX) Quarterly 10-Q Report - Quartzy
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):